Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life

References

• BuistAMcBurnieMVollmerWInternational variation in the prevalence of COPD (the BOLD study): a population-based prevalence studyLancet200737074175017765523
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADMeasuring the global burden of diseaseN Engl J Med201336944845723902484
   PubMed Web of Science ®Google Scholar
• HoggJCMacklemPTThurlbeckWMSite and nature of airway obstruction in chronic obstructive lung diseaseN Engl J Med1968278135513605650164
   PubMed Web of Science ®Google Scholar
• CosioMGhezzoHHoggJCThe relations between structural changes in small airways and pulmonary-function testsN Engl J Med197829812771281651978
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med20043502645265315215480
   PubMed Web of Science ®Google Scholar
• McDonoughJEYuanRSuzukiMSmall-airway obstruction and emphysema in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201136515671575
   Google Scholar
• VestboJHurdSAgustìAGGlobal Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD Executive SummaryAm J Respir Crit Care Med201318734736522878278
   PubMed Web of Science ®Google Scholar
• SiafakasNMVermeirePPrideNBOptimal assessment and management of chronic obstructive pulmonary disease (COPD)Eur Respir J19958139814207489808
   PubMed Web of Science ®Google Scholar
• BettoncelliGBlasiFBrusascoVThe clinical and integrated management of COPD. An official document of AIMAR, AIPO, SIMeR, SIMGSarcoidosis Vasc Diffuse Lung Dis201431Suppl 1321
   Google Scholar
• PellegrinoRViegiGBrusascoVInterpretative strategies for lung function testsEur Respir J20052694896816264058
   PubMed Web of Science ®Google Scholar
• FletcherCPetoRTinkerCThe Natural History of Chronic Bronchitis and Emphysema An Eigth-Year Study of Early Chronic Obstructive Lung Disease in Working Men in LondonOxford, UKOxford University Press1976
   Google Scholar
• TantucciCModinaDLung function decline in COPDInt J COPD201279599
   Google Scholar
• MillerARaskinJMThe natural history of COPD: confirming and going beyond Fletcher and PetoEur Respir J20144428038325082904
   PubMed Web of Science ®Google Scholar
• MacklemPTTherapeutic implications of the pathophysiology of COPDEur Respir J20103567668020190332
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med20103631128113820843247
   PubMed Web of Science ®Google Scholar
• HanMKKazerooniEALynchDAChronic obstructive pulmonary disease exacerbations in the COPD Gene Study: associated radiologic phenotypesRadiology201126127428221788524
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMSantangeloGSalmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response studyRespir Med1995893573627638371
   PubMed Web of Science ®Google Scholar
• VestboJTORCH Study GroupThe TORCH (TOwards a Revolution in COPD Health) survival study protocolEur Respir J20042420621015332386
   PubMed Web of Science ®Google Scholar
• AugustiAFabbriLMInhaled steroids in COPD: when should they be used?Lancet2014286987125439566
   PubMed Web of Science ®Google Scholar
• KaikGCombined administration of ipratropium bromide (SCH1000) and fenoterol in patients with chronic obstructive airway diseaseMed Klin Wochenschr197587653656
   PubMed Web of Science ®Google Scholar
• American College of Chest PhysiciansIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study GroupChest1994105141114198181328
   PubMed Web of Science ®Google Scholar
• BenayounSErnstPSuissaSThe impact of combined inhaled broncho-dilator therapy in the treatment of COPDChest2001119859211157588
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic ob struc tive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• CooperCBThe connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and functionAm J Med2006119Suppl 1213116996896
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAlbertPWalkerPPBronchodilator reversibility in chronic obstructive pulmonary diseaseLancet Respir Med2013156457324461617
   PubMed Web of Science ®Google Scholar
• TantucciCDuguetASimilowskiTZelterMDerenneJ-PMilic-EmiliJEffect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary diseaseEur Respir J1998127998049817148
   PubMed Web of Science ®Google Scholar
• O’DonnellDEVoducNFitzpatrickMWebbKAEffect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary diseaseEur Respir J200424869415293609
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenAEffects of tiotropium on lung hyperinflation, dyspnoea, and exercise tolerance in COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• RossiACentanniSCerveriIAcute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropiumRespir Med2012106849022035851
   PubMed Web of Science ®Google Scholar
• O’DonnellDELavenezianaPOraJWebbKALamYMOfirDEvaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPDThorax20096421622319052054
   PubMed Web of Science ®Google Scholar
• O’DonnellDELavenezianaPLung hyperinflation in COPD: the impact of pharmacotherapyEur Respir Rev2006158589
   Google Scholar
• BeehKMWagnerFKhindriSDrollmannAFEffect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPDCOPD2011834034521793716
   PubMedGoogle Scholar
• WedzichaJADecramerMSeemugalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J2012401545155422835613
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther20102325726720381630
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLMateraMGβ2-adrenoceptor agonists: current and future directionBr J Pharmacol201116341721232045
   PubMed Web of Science ®Google Scholar
• MeursHOenemaTAKistemakerLEGosensRA new perspective on muscarinic receptor antagonism in obstructive airways diseasesCurr Opin Pharmacol20131331632323643733
   PubMed Web of Science ®Google Scholar
• MeursHDekkersBGMaarsinghHHalaykoAJZaagsmaJGosensRMuscarinic receptors on airway mesenchymal cells: novel findings for an ancient targetPulm Pharmacol Ther20132614515522842340
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGThe effective treatment of COPD: anti-cholinergics and what else?Drug Discov Today Ther Strateg20063277286
   Google Scholar
• EastonPAJadueCDhingraSAnthonisenNRA comparison of the bronchodilating effect of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide) given by aerosol alone or in sequenceN Engl J Med19853157357392943994
   PubMed Web of Science ®Google Scholar
• IngramRHMcFaddenERPredominantly large versus small airways responses in normal subjectsSadoulPMilic-EmiliJSimonssonBGClarkTJHSmall Airways in Health and DiseaseAmsterdam, The NetherlandsExcerpta Medica1979
   Google Scholar
• BarnesPJDistribution of receptors targets in the lungProc Am Thorac Soc2004134535116113456
   PubMedGoogle Scholar
• KeatingGMTiotropium bromide inhalation powder. A review of its use in the management of chronic obstructive pulmonary diseaseDrugs20127227330022217233
   PubMed Web of Science ®Google Scholar
• KeatingMGTiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary diseaseDrugs2014741801181625300412
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedereBGlaabTfor the POET-COPD investigatorsTiotropium versus salmeterol for prevention of exacerbations of COPDN Engl J Med20113641093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMChapmanKRFrithPOnce daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomized, blinded, parallel-group studyLancet Respir Med2013152453324461613
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMASeemugalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• RossiAPoleseGIndacaterol: a comprehensive reviewInt J COPD20138353363
   Google Scholar
• TaskinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for COPD: current evidence and future perspectivesBr J Clin Pharmacol1162014 Epub ahead of print
   Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDon behalf of the INTRUST-1 and INTRUST-2 Study InvestigatorsConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaForceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax2010651086109120978028
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• BanerjiDFogelRBeehKMDual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of latest clinical dataClin Invest20144511533
   Google Scholar
• UlrikCSClinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic reviewInt J COPD20149331338
   Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med2014247248624835833
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/villanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis2014816918125452426
   PubMed Web of Science ®Google Scholar
• BlairHADeeksEDUmeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary diseaseDrugs201575617425398674
   PubMed Web of Science ®Google Scholar
• VinkenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J COPD20149215228
   Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J COPD20127729741
   Google Scholar
• DahlRJadeyelDAlagappanVKTChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its mono components indacaterol and glycopyrronium: the BEACON studyInt J COPD20138501508
   Google Scholar
• RenardDLoobyMKramerBLawrenceDMorrisDStanskiDRCharacterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approachesRespir Res2011125421518459
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLSegretiAFaccioloFRoglianiPMateraMGTranslational study searching for synergy between glycopyrronium and indacaterolCOPD9152014 Epub ahead of print
   PubMedGoogle Scholar
• GlaabTVogelmeierCBuhlROutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsRespir Res2010117920565728
   PubMed Web of Science ®Google Scholar
• FramptonJEQVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary diseaseDrugs20147446548824604791
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J20083141646818238951
   PubMed Web of Science ®Google Scholar
• MahalerDAMeasurement of dyspnea: clinical ratingsMahalerDADyspnea: Mechanisms, Measurement, and Management2nd edNew York, NY, USATaylor & Francis Inc2005
   Google Scholar
• MahlerDAWardJWatermannLAPatient-reported dyspnea in COPD reliability and association with stage of diseaseChest20091361473147919696126
   PubMed Web of Science ®Google Scholar
• MahalerDAWardJFierro-CarrionGDevelopment of self-administered versions of modified baseline and transitional dyspnea indexes in COPDJ COPD2004118
   Google Scholar
• JonesPWQuality of life measurement for patients with diseases of the airwaysThorax1991466766821835178
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMThe Saint George’s Respiratory QuestionnaireRespir Med199185Suppl B25311759018
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahalerDWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med201418925025524383418
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD. A systematic reviewChest201414630931724556877
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med20131071558156723867808
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomized, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• ObaYLoneNAComparative effect of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysisInt J COPD20149469479
   Google Scholar
• MahalerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnea in COPD: the BLAZE studyEur Respir J2014431599160924176997
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoAGlobal strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. GOLD executive summaryAm J Respir Crit Care Med200717653255517507545
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients; the BRIGHT studyRespir Med201410858459224534204
   PubMed Web of Science ®Google Scholar
• OraJLavenezianaPOfirDDeesomchokAWebbKO’DonnellDECombined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise toleranceAm J Respir Crit Care Med200918096497119897773
   PubMed Web of Science ®Google Scholar
• OfirDLavenezianaPWebbKLamYMO’DonnellDEMechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD I stage chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200817762262918006885
   PubMed Web of Science ®Google Scholar
• GuenetteJAChinRCChengSMechanisms of exercise intolerance in global initiative for chronic obstructive lung disease grade 1 COPDEur Respir J2014441177118725142487
   PubMed Web of Science ®Google Scholar
• O’DonnellDELavenezianaPPhysiology and consequences of lung hyperinflation in COPDEur Respir Rev2006156167
   Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA1448 compared with the free combination of one-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomized, non-inferiority studyThorax20157031131925677679
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGBronchodilators: current and futureClin Chest Med20143519120124507846
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline CentreChronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary careLondon, UKNational Clinical Guideline Centre2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed April 24, 2015
   Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACalverleyPThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR): a large scale, randomized, controlled, parallel-group trial design and rationaleRespir Res2013144023547660
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTrial of Inhaled Steroids and Long-Acting Beta2 Agonists Study GroupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet200336144945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• CorradoARossiAHow far is real life from COPD therapy guidelines? An Italian observational studyRespir Med2012106e989e997
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• ErnstPSaadNSuissaSInhaled corticosteroids in COPD: the clinical evidenceEur Respir J20154552553725537556
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMVestboJA novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME studyEur Respir J201342Suppl 57P696
   Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• PavkovRMuellerSFiebichKCharacteristics of a capsule based dry powder inhaler for the delivery of indacaterolCurr Med Res Opin2010262527253320843166
   PubMed Web of Science ®Google Scholar
• HamiltonMPrimeDBogalo HuescarMIn vitro delivery performance of umeclidinium and umeclidinium/vilanterol from a dry powder inhaler using the Electronic Lung breathing simulator to replicate inhalation profiles from patients with varying COPD severityAm J Respir Crit Care Med2013187A4281
   Web of Science ®Google Scholar
• SvedsaterHDalePGarrillKQualitative assessment of attributes and ease of use of the Ellipta™ dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• DalbyRSpallekMVoshaarTA review of the development of Respimat Soft Mist inhalerInt J Pharm20042831915363496
   PubMed Web of Science ®Google Scholar
• HodderRPriceDPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhalerInt J Chron Obstruct Pulmon Dis2009438139019888356
   PubMedGoogle Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med20141081498150725135743
   PubMed Web of Science ®Google Scholar